Floatz logo

[18F]ACI-19626

Alzheimer Disease

AC Immune SAUNKNOWNEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

298 Active assets in the Alzheimer Disease cohort.

Asset / SponsorPhaseRating
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE
Akiva Mintz
Phase 4BBB
Memantine
Carnot Laboratories
Phase 4BBB
Escitalopram
NYU Langone Health
Phase 4BBB
Flortaucipir
Eli Radiopharma
Phase 4BBB
Rivastigmine
Anhui Provincial Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

[18F]ACI-19626 is also rated in:

frontotemporal dementiaActive
C
Indicative · Early Phase 1
39 / 100
View asset →
TDP-43 proteinopathyActive
C
Indicative · Early Phase 1
39 / 100
View asset →
amyotrophic lateral sclerosisActive
C
Indicative · Early Phase 1
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →